共 50 条
- [21] A Study in Healthy Volunteers To Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses of GSK1292263, a Novel GPR119 AgonistDIABETES, 2010, 59 : A22 - A22Nunez, Derek J.Lewis, Eric W.Swan, SuzanneBush, Mark A.Cannon, CourtneyMcMullen, Susan L.Collins, David A.Feldman, Paul L.
- [22] Ragaglitazar:: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetesJOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (11): : 1244 - 1256Skrumsager, BKNielsen, KKMüller, MPabst, GDrake, PGEdsberg, B
- [23] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN HEALTHY MALE VOLUNTEERS.CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S78 - S78Koenen, R.Fowler, A.Gupta, A.Hilbert, J.
- [24] Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes MellitusJOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06): : 601 - 610Devineni, DamayanthiCurtin, Christopher R.Polidori, DavidGutierrez, Maria J.Murphy, JosephRusch, SarahRothenberg, Paul L.
- [25] Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjectsDIABETES, 2007, 56 : A161 - A161Boulton, David W.Geraldes, Margarida
- [26] Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteersNAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,Schulze, FriedrichSchaible, JenniferGoettel, MarkusTanaka, YukoHohl, KathrinSchultz, ArminJang, In-Jin
- [27] Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes MellitusCLINICAL THERAPEUTICS, 2014, 36 (11) : 1606 - 1615Sarashina, AkikoUeki, KohjiroSasaki, TomohiroTanaka, YukoKoiwai, KazukiSakamoto, WataruWoerle, Hans J.Salsali, AfshinBroedl, Uli C.Macha, Sreeraj
- [28] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Tissue Kallikrein-1 (DM199) in Healthy Volunteers and Patients with Type 2 Diabetes MellitusDIABETES, 2014, 63 : A250 - A251Robbins, Mark S.Charles, MatthewVan Vliet, AndreHadi, SalahKim, Dennis D.
- [29] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB InhibitorJOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565Dennie, JustinVandell, Alexander G.Inoue, SatoshiGajee, RoohiPav, JosephZhang, GeorgeZamora, CynthiaMasuda, NobuhisaUchiyama, MinoruYamada, MakikoSenaldi, Giorgio
- [30] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 10773, a Sodium-Glucose Co-Transporter Inhibitor (SGLT-2), in Healthy VolunteersDIABETES, 2010, 59 : A155 - A155Port, AndreasMacha, SreerajSeman, LeoNehmiz, GerhardSimons, GudrunKoegel, AnjaHarder, DanielaRen, BailuoIovino, MarioPinnetti, SabineDugi, Klaus A.